Subscribe to RSS
DOI: 10.1055/s-0028-1105890
© Georg Thieme Verlag KG Stuttgart · New York
MCI-plus: leichte kognitive Beeinträchtigung mit rascher Progredienz
Teil I: Prävention und TherapieMCI-plus: mild cognitive impairment with rapid progression. Part I: prevention and therapyPublication History
eingereicht: 15.6.2008
akzeptiert: 1.9.2008
Publication Date:
17 December 2008 (online)

Zusammenfassung
Die leichte kognitive Beeinträchtigung (Mild Cognitive Impairment, MCI) ist im höheren Lebensalter häufig und viele Betroffene weisen Prädiktoren für eine rasche Progression zur Demenz auf („MCI-plus”). Aufgrund demografischer Veränderungen und eines anwachsenden Problembewusstseins in der Bevölkerung wird MCI-plus in den nächsten Jahren in vielen Bereichen der Medizin deutlich weiter an Bedeutung gewinnen, während sich die Möglichkeiten einer Frühdiagnose schneller entwickeln als die Einführung kausaler Interventionen gegen zugrunde liegende neurodegenerative und vaskuläre Hirnveränderungen. Bei den meisten dieser Patienten bestehen aber symptomatisch beeinflussbare oder bereits heute kausal behandelbare Grund- und Begleiterkrankungen. Wir gehen auf neuropsychologische und psychopharmakologische Therapiemöglichkeiten ein, sowie auf die Chancen einer konsequenten somatischen Behandlung relevanter internistischer und neurologischer Faktoren.
Summary
Mild Cognitive Impairment (MCI) is a prevalent problem in the elderly and many patients show predictors of rapid cognitive decline („MCI-plus”). MCI-plus represents a syndrome with growing importance in an ageing society, which will increasingly affect primary medicine and most other clinical specialties. We will have to face the dilemma of fast progress in the field of neurodiagnostics with innovative therapeutic strategies lagging behind. Psychological and medical co-morbidity in MCI-plus will therefore offer important opportunities to delay and to avoid the manifestation of dementia. We will review and discuss current training and treatment options including symptomatic and causal interventions.
Schlüsselwörter
leichte kognitive Beeinträchtigung - mild cognitive impairment - MCI-plus - Neuropsychologie - Progression - Prävention - Demenz - Morbus Alzheimer - Alzheimer-Phobie
Keywords
mild cognitive impairment - MCI-plus - neuropsychology - progression - prevention - dementia - Alzheimer’s disease - Alzheimer phobia
Literatur
- 1
Adler G, Chwalek K, Jajcevic A. et al .
Six-month course of mild cognitive impairment
and affective symptoms in late-life depression.
Eur Psychiat.
2004;
19
502-505
MissingFormLabel
- 2
Aisen P S, Thal L J, Ferris S H. et al .
Rofecoxib in patients with
mild cognitive impairment: further analyses of data from a randomized,
double-blind trial.
Curr Alzheimer Ther.
2008;
5
73-82
MissingFormLabel
- 3
Artero S, Ancelin M L, Portet F. et al .
Risk profiles for mild cognitive impairment
and progression to dementia are gender specific.
J Neurol
Neurosurg Psychiatry.
2008;
, doi:
10.1136/jnnp.2007.136903
MissingFormLabel
- 4
Barnes D E, Alexopoulos G S, Lopez O. et al .
Depressive symptoms, vascular disease and
mild cognitive impairment.
Arch Gen Psychiat.
2006;
63
273-280
MissingFormLabel
- 5
Baumgart P, Helgenberger F, Weyerer S. et al .
The course of cognition and depression
in elderly patients with affective disturbances and mild cognitive
impairment.
Int J Geriatr Psychiatry.
1995;
10
20-21
MissingFormLabel
- 6
Belleville S, Gilbert B, Fontaine F. et al .
Improvement of episodic memory in persons
with mild cognitive impairment and healthy older adults: evidence
from a cognitive intervention program.
Dement Geriat Cogn
Disord.
2006;
22
486-499
MissingFormLabel
- 7
Bhalla R K, Butters M A, Mulsant B H. et al .
Persistence of neuropsychologic deficits
in the remitted state of late-life depression.
Am J Geriatr
Psychiat.
2006;
14
419-427
MissingFormLabel
- 8
Bickel H, Mösch E, Seigerschmidt E, Siemen M, Förstl H.
Prevalence and persistence of mild cognitive
impairment among elderly patients in general hospitals.
Dement
Geriatr Cogn Disord.
2006;
21
242-50
MissingFormLabel
- 9
Bickel H.
Rauchen und Alkoholkonsum als Risikofaktoren einer Demenz im
Alter.
Sucht.
2006;
52
48-59
MissingFormLabel
- 10
Bosch J, Yusuf S, Pogue J. et
al .
Use of ramipril in preventing stroke: double-blind
randomised trial.
Brit J Med.
2002;
324
699-702
MissingFormLabel
- 11
Cipriani G, Bianchetti A, Trabucchi M.
Outcomes of computer-based cognitive rehabilitation program
on Alzheimer’s disease patients compared with those on
patients affected by mild cognitive impairment.
Arch Gerontol
Geriatr.
2006;
43
327-35
MissingFormLabel
- 12
Clarnette R M, Almeida O P, Forstl H, Paton A, Martins R.
Clinical characteristics of individuals with subjective memory
loss in Western Australia.
Int J Geriat Psychiat.
2001;
16
168-174
MissingFormLabel
- 13
Collins R, Armitage J, Parish S, Sleigh P, Peto R.
MRC/BHF Heart Protection Study of cholesterol-lowering
with simvastatin in 5963 people with diabetes: a randomised Placebo-controlled
trial.
Lancet.
2003;
361
2005-2016
MissingFormLabel
- 14
Dufouil C, Chalmers J, Coskun O. et al .
PROGRESS MRI Substudy Investigators. Effects
of blood pressure lowering on cerebral white matter hyperintensities
in patients with stroke: the PROGRESS (Perindopril Protection Against
Recurrent Stroke Study) Magnetic Resonance Imaging Substudy.
Circulation.
2005;
112
1644-50
MissingFormLabel
- 15
Egert S, Wagenpfeil S, Förstl H.
Cholinesterase-Inhibitoren und Alzheimer Demenz: Meat-Analyse
zu Wirksamkeitsnachweis, Ursprung und Ergebnisverzerrung in publizierten
Studien.
Dtsch Med Wochenschr.
2007;
132
1207-13
MissingFormLabel
- 16 Etgen T, Brönner M, Sander D. et al .Somatische Faktoren bei leichter kognitiver
Störung. Fortschr Neurol Psychiat 2009, in press
MissingFormLabel
- 17
Feldman H H, Ferris S, Winblad B. et al .
Effect of rivastigmine on delay of diagnosis
of Alzheimer’s disease from mild cognitive impairment:
the InDDEx study.
Lancet Neurol.
2007;
6
501-12
MissingFormLabel
- 18
Forette F, Seux M L, Staessen J A. et al .
Prevention of dementia in
randomised double-blind Placebo-controlled Systolic Hypertension
in Europe (SYST-EUR) trial.
Lancet.
1998;
352
1347-51
MissingFormLabel
- 19
Förstl H, Bickel H, Frölich L. et al .
Leichte kognitive Beeinträchtigung
mit Vorzeichen rascher Verschlechterung.
Dtsch Med Wochenschr.
2007;
133
431-436
MissingFormLabel
- 20
Förstl H.
Behandlungs- und Versorgungsstrategien bei Alzheimer und verwandten
Demenzen.
Nervenarzt.
2008;
79
617-29
MissingFormLabel
- 21
Furio A M, Brusco L I, Cardinali D P.
Possbile therapeutic value of melatonin in
mild cognitive impairment: a retrospective study.
J Pineal
Res.
2007;
43
404-9
MissingFormLabel
- 22
Gomez-Isla T, Blesa R, Boada M. et
al .
A randomized double-blind, placebo controlled trial
of triflusal in mild cognitive impairment.
Alzh Dis Assoc Disord.
2008;
22
21-9
MissingFormLabel
- 23
Kivipelto M, Ngandu T, Laatikainen T, Winblad B, Soininen H, Tuomilehto J.
Risk score fort he
prediction of dementia risk in 20 years among middle aged people:
a longitudinal, population-based study.
Lancet Neurology.
2006;
5
735-741
MissingFormLabel
- 24
Lee J S, Potter G G, Wagner H R. et al .
Persistent mild cognitive
impairment in geriatric depression.
Int Psychogeriatr.
2007;
19
125-135
MissingFormLabel
- 25
Lyle S, Grizzell M, Willmott S. et al .
Treatment of a whole population sample
of Alzheimer’s disease with donepezil over a 4-year period:
lessons learned.
Dementia Geriat Cogn Disord.
2008;
25
226-31
MissingFormLabel
- 26
McMahon J A, Green T J, Skeaff C M, Knight R G, Mann J I, Williams S M.
A controlled trial of homocysteine lowering and cognitive performance.
N Engl J Med.
2006;
354
2764-2772
MissingFormLabel
- 27
Modrego P J, Ferrandez J.
Depression in patients
with mild cognitive impairment increases the risk of developing
dementia of Alzheimer type; a prospective cohort study.
Arch
Neurol.
2004;
61
1290-1293
MissingFormLabel
- 28
Mowla A, Mosavinasab M, Hagshenas H, Haghighi A B.
Does serotonin
augmentation have any effect on cognition and activities of daily
living in Alzheimer’s dementia? A double blind, placebo-controlled
clinical trial.
J Clin Psychopharmacol.
2007;
27
484-87
MissingFormLabel
- 29
Olazarán J, Muñiz R, Reisberg B. et al .
Benefits of cognitive-motor intervention
in MCI and mild to moderate Alzheimer disease.
Neurology.
2004;
63
2348-53
MissingFormLabel
- 30
Ownby R L, Crocco E, Acevedo A. et al .
Depression and risk for Alzheimer disease:
systematic review, meta-analysis, and metaregression analysis.
Arch Gen Psychiatry.
2006;
63
530-538
MissingFormLabel
- 31
Rapp M A, Schnaider-Beeri M, Grossman H T. et al .
Increased plaques and tangles
in patients with Alzheimer’s disease with a lifetime history
of major depression.
Arch Gen Psychiat.
2006;
63
161-167
MissingFormLabel
- 32
Rapp S, Brenes G, Marsh A P.
Memory enhancement training for older adults with mild cognitive
impairment: a preliminary study.
Aging Ment Health.
2002;
6
5-11
MissingFormLabel
- 33
Ravaglia G, Forti P, Lucicesare A. et al .
Physical activity and dementia risk in
the elderly: findings from a prospective Italian study.
Neurology.
2008;
70
1786-94
MissingFormLabel
- 34
Reger M A, Watson G S, Green P S. et al .
Intranasal insulin improves
cognition and modulates beta-amyloid in early AD.
Neurology.
2008;
5
440-8
MissingFormLabel
- 35
Riedel O, Klotsche J, Spottke A. et al .
Cognitive impairment in 873 patients with
idiopathic Parkinson’s diease: results from the German
Study on Epidemiology of Parkinson’s Disease with Dementia
(GEPAD).
J Neurol.
2008;
2
255-64
MissingFormLabel
- 36
Rozzini L, Costardi D, Chilovi B V. et al .
Efficacy of cognitive rehabilitation in patients
with mild cognitive impairment treated with cholinesterase inhibitors.
Int J Geriat Psychiat.
2007;
22
356-60
MissingFormLabel
- 37
Saxby B K, Harrington F, Wesnes K A. et al .
Candesartan and cognitive decline in older
patients with hypertension: a sub-study of the SCOPE trial.
Neurology.
2008;
70
1858-66
MissingFormLabel
- 38
Schönknecht P, Pantel J, Kaiser E. et al .
Increased tau protein differentiates mild
cognitive impairment from geriatric depression and predicts conversion
to dementia.
Neurosci Lett.
2007;
416
39-42
MissingFormLabel
- 39
Shepherd J, Blauw G J, Murphy M B, Bollen E L. et
al .
Pravastatin in elderly individuals at risk of vascular
disease (PROSPER): a randomised controlled trial.
Lancet.
2002;
360
1623-1630
MissingFormLabel
- 40
Solfrizzi V, Colaciccio A M, D’Intonron A. et al .
Dietary fatty acids intakes
and rate of mild cognitive impairment. The Italian Longitudinal
Study on Aging.
Exp Gerontol.
2006;
41
619-27
MissingFormLabel
- 41
Sun X, Steffens D C, Au R. et al .
Amyloid-associated depression: a prodromal depression
of Alzheimer disease?.
Arch Gen Psychiat.
2008;
65
542-50
MissingFormLabel
- 42
Troyer A K, Murphy K J, Anderson N D, Moscovitch M, Craik F IM.
Changing everyday memory behaviour
in amnestic mild cognitive impairment: A randomized controlled trial.
Neuropsychol Rehabilitation.
2008;
18
65-88
MissingFormLabel
- 43
Tzourio C, Anderson C, Chapman N. et al .
Effects of blood pressure lowering with
perindopril and indapamide therapy on dementia and cognitive decline
in patients with cerebrovascular disease.
Arch Intern
Med.
2003;
163
1069-75
MissingFormLabel
- 44
Marum, R.
Current and future therapies in Alzheimer’s disease.
Fundament Clin Pharmacol.
2008;
22
265-274
MissingFormLabel
- 45
Van Uffelen J G, Chinapaw M J, van
Mechelen W, Hopman-Rock M.
Walking or vitamin B for cognition in older adults with mild
cognitive impairment? A randomised controlled trial.
Brit
J Sports Med.
2008;
42
344-51
MissingFormLabel
- 46
Velandai K, Stephen J, Quinn S J, Donnan G A, Saling M M, Thrift A G.
Long-Term
Cognitive Transitions, Rates of Cognitive Change, and Predictors
of Incident Dementia in a Population-Based First-Ever Stroke Cohort.
Stroke.
2006;
37
2479-2483
MissingFormLabel
- 47
Werheid K, Thöne-Otto A IT.
Kognitives
Training bei Alzheimer-Demenz.
Nervenarzt.
2006;
77
549-557
MissingFormLabel
- 48 Weyerer S, Eifflaender-Gorfer S, Köhler L. et al .Prevalence and risk factors for
depression in non-demented primary care attenders aged 75 years and
older. J Affect Dis 2009, in press
MissingFormLabel
- 49
Winblad B, Gauthier S, Scinto L. et al .
Safety and efficacy of galantamine in subjects
with mild cognitive impairment.
Neurology.
2008;
27
2024-35
MissingFormLabel
Prof. Dr. Hans Förstl
Klinik und Poliklinik für Psychiatrie
und Psychotherapie, Klinikum Rechts der Isar, Technische
Universität München
Ismaningerstr. 22
81675 München
Phone: 089/4140-4200
Fax: 089/4140-4837
Email: hans.foerstl@lrz.tu-muenchen.de